Article

Dr. Mulcahy to join Phoenix urology practice

John J. Mulcahy, MD, PhD, has announced that he will be leaving Indiana University Medical Center and will move his practice to Phoenix, where he will be joining Urology Associates Ltd.

John J. Mulcahy, MD, PhD, has announced that he will be leaving Indiana University Medical Center and will move his practice to Phoenix, where he will be joining Urology Associates Ltd. Dr. Mulcahy said he will continue his practice of managing complex penile implant and artificial urinary sphincter cases and the surgical treatment of Peyronie’s disease. Dr. Mulcahy joined the Indiana University staff in 1978 and is currently professor of urology. He has pioneered a number of surgical innovations related to prosthetic devices. He will join Urology Associates in January 2006.

Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Justin Dubin, MD, answers a question during a video interview
Phillip M. Pierorazio, MD, answers a question during a video interview
Michael Jenson, PA-C, answers a question during a Zoom video interview
Prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Related Content
JANX007 demonstrates encouraging clinical activity in mCRPC
December 3rd 2024

JANX007 demonstrates encouraging clinical activity in mCRPC

Hannah Clarke
Data showed that all patients achieved a PSA decline of at least 50%.
Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer
December 2nd 2024

Pembro/chemo combo shows promise in small cell/neuroendocrine bladder and prostate cancer

Hannah Clarke
“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Phase 2 trial launches of autologous prostate cancer vaccine
November 27th 2024

Phase 2 trial launches of autologous prostate cancer vaccine

Hannah Clarke
The phase 2 CELLVX-230 trial is exploring the potential of FK-PC101 to delay or prevent prostate cancer recurrence following prostatectomy.
Doctor using calculator | Image Credit: © NIKCOA - stock.adobe.com
November 27th 2024

Final rule: Conversion factor set for 2.83% reduction in 2025

Jonathan Rubenstein, MD Mark Painter
"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and Mark Painter.
© 2024 MJH Life Sciences

All rights reserved.